Multiplexed antibody discovery using single-cell Nanovials
Official title: Multiplexed analysis of antibody secreting cells for enhanced function first antibody discovery
Funded at Partillion Bioscience Corporation · NIH-11185485 · Data updated 2026-11-12
A patient-friendly look at a new method to speed up creating monoclonal antibodies by analyzing individual antibody-secreting cells more efficiently.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Partillion Bioscience Corporation NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | July 16, 2026 |
| Project end | June 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $306,865 |
| NIH project number | 1R43AI186929-01A1 |
| Project ID | NIH-11185485 on NIH RePORTER |
Who could benefit from this research
✓Could help
This grant is a preclinical technology development project; it does not require patient participants.
✕Less likely to help
Patients are not enrolled in this phase; benefits come from faster development of antibody therapies in the future.
What this research studies
This grant focuses on improving Nanovial technology to screen single cells that produce antibodies, making the discovery process faster and more cost-effective. It explores new chemical formulations to use streptavidin-antigen complexes and develops multiepitope sequencing readouts to better understand how antibodies interact with targets early in discovery. The work builds on UCLA-developed technology to enable high-plex, single-cell assays that could shorten the path from discovery to potential therapies. If successful, the approach could accelerate development of antibody-based diagnostics and treatments. The project is done by Partillion Bioscience in Los Angeles under an NIH R43 award to advance a practical tool for antibody discovery.
Why it matters
Potential benefit: If successful, this technology could speed up creating safe and effective antibody therapies for patients.
How similar studies have gone: Preclinical single-cell antibody screening technologies have shown promise in speeding discovery, with ongoing optimization.
Where this research is happening
-
Partillion Bioscience Corporation
Los Angeles, United States Active
Researchers
- Principal investigator: De Rutte, Joseph — Partillion Bioscience Corporation
- Study coordinator: De Rutte, Joseph
Related research
Other NIH-funded projects on the same topics.
-
Nanovial tools to map how single cells talk to each other at scale
New technology to study how individual cells communicate and affect each other, using easy-to-use nanovial kits with common single-cell sequencing methods.
-
Accelerating antibody discovery using memory B cells
A new program aims to speed up finding useful monoclonal antibodies by leveraging memory B cells with innovative tools to sort and test many cells at once.
-
Improving the discovery of effective antibody therapies
This study is working on a faster and easier way to find important proteins called monoclonal antibodies, which help create better treatments for patients, so you can get more effective therapies more quickly and at a lower cost.
-
Exploring how antibody sequences work at the single-cell level using new technology
This study is testing a new technology that helps scientists look closely at how individual antibodies work, which could lead to quicker and better treatments for diseases like autoimmune disorders and cancer, ultimately helping patients get the right therapies faster.
-
Using hydrogel microparticles to improve CAR-T cell therapies for cancer treatment
This study is working on improving CAR-T cell therapies for cancer by using special technology to find the best CAR-T cells that can fight tumors, which could lead to better treatments for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.